123 related articles for article (PubMed ID: 37099013)
1. Adjunctive Cilostazol in Patients With High Residual Platelet Reactivity After Drug-Eluting Stent Implantation: A Randomized, Open-Label, Single-Center, Prospective Study (ADJUST-HPR).
Long Zhe G; Hau Yu L; Lee DH; Kim MH; Serebruany V
Am J Ther; 2024 May-Jun 01; 31(3):e229-e236. PubMed ID: 37099013
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive Cilostazol in Patients With High Residual Platelet Reactivity After Drug-Eluting Stent Implantation: A Randomized, Open-Label, Single-Center, Prospective (ADJUST-HPR) Study: Erratum.
Am J Ther; 2024 Mar-Apr 01; 31(2):e207. PubMed ID: 38518278
[No Abstract] [Full Text] [Related]
3. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
[TBL] [Abstract][Full Text] [Related]
4. Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy.
Hernandez-Suarez DF; Núñez-Medina H; Scott SA; Lopez-Candales A; Wiley JM; Garcia MJ; Melin K; Nieves-Borrero K; Rodriguez-Ruiz C; Marshall L; Duconge J
Drug Metab Pers Ther; 2018 Mar; 33(1):49-55. PubMed ID: 29408797
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with Renal Impairment during Dual Antiplatelet Therapy.
Guo LZ; Kim MH; Kim TH; Park JS; Jin E; Shim CH; Choi SY; Serebruany VL
Nephron; 2016; 132(3):191-7. PubMed ID: 26914786
[TBL] [Abstract][Full Text] [Related]
6. Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease.
Lee SP; Suh JW; Park KW; Lee HY; Kang HJ; Koo BK; Chae IH; Choi DJ; Rha SW; Bae JW; Cho MC; Kwon TG; Bae JH; Kim HS;
Trials; 2010 Aug; 11():87. PubMed ID: 20735821
[TBL] [Abstract][Full Text] [Related]
7. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
8. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
[TBL] [Abstract][Full Text] [Related]
9. Body Mass Index and Plasma P-Selectin before Coronary Stenting Predict High Residual Platelet Reactivity at 6 Months on Dual Antiplatelet Therapy.
Golukhova EZ; Grigoryan MV; Ryabinina MN; Bulaeva NI; Serebruany VL
Cardiology; 2018; 139(2):132-136. PubMed ID: 29334682
[TBL] [Abstract][Full Text] [Related]
10. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials.
Bangalore S; Singh A; Toklu B; DiNicolantonio JJ; Croce K; Feit F; Bhatt DL
Open Heart; 2014; 1(1):e000068. PubMed ID: 25332804
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.
Gremmel T; Koppensteiner R; Panzer S
PLoS One; 2015; 10(6):e0129666. PubMed ID: 26058047
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors.
Wadowski PP; Pultar J; Weikert C; Eichelberger B; Lang IM; Koppensteiner R; Panzer S; Gremmel T
J Cardiovasc Pharmacol Ther; 2021 May; 26(3):260-268. PubMed ID: 33107322
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.
Jeong YH; Lee SW; Choi BR; Kim IS; Seo MK; Kwak CH; Hwang JY; Park SW
J Am Coll Cardiol; 2009 Mar; 53(13):1101-9. PubMed ID: 19324253
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
Chen J; Meng H; Xu L; Liu J; Kong D; Chen P; Gong X; Bai J; Zou F; Yang Z; Li C; Eikelboom JW
J Thromb Thrombolysis; 2015 Jan; 39(1):23-34. PubMed ID: 24869717
[TBL] [Abstract][Full Text] [Related]
16. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
[TBL] [Abstract][Full Text] [Related]
17. Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.
Yang TH; Kim DI; Kim DK; Jang JS; Kim U; Seol SH; Kim DK; Hong GR; Park JS; Shin DG; Kim YJ; Cho YK; Nam CW; Hur SH; Kim KB; Kim DS
Korean J Intern Med; 2011 Jun; 26(2):145-52. PubMed ID: 21716590
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Desai B; Tello-Montoliu A; Rollini F; Angiolillo DJ
Catheter Cardiovasc Interv; 2013 Jan; 81(1):42-9. PubMed ID: 22431415
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 1-month vs. 12-month dual antiplatelet therapy after implantation of drug-eluting stents in patients with acute coronary syndrome: the ULTIMATE-DAPT trial.
Vranckx P; Valgimigli M
Eur Heart J Acute Cardiovasc Care; 2024 May; 13(4):368-369. PubMed ID: 38598480
[No Abstract] [Full Text] [Related]
20. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
Nakagawa I; Wada T; Park HS; Nishimura F; Yamada S; Nakagawa H; Kichikawa K; Nakase H
J Vasc Surg; 2014 Mar; 59(3):761-7. PubMed ID: 24239116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
